By Yusuff Moshood –
In recognition of its outstanding performance and contribution to health care delivery in Lagos State, Olpharm Nigeria Limited was recently awarded the 2013 Lagos State Health Merit Award.
The award was presented by the State Governor, BabatundeFashola, during an event held at City Hall, Lagos, last December.
According to the state government, the award was conferred on Olpharm for providing exemplary support in health care services and for loyalty and dedication to duty.
Speaking with Pharmanews in an exclusive interview on the award, Pharm. Johnson Olusetire, managing director/CEO, Olpharm Nigeria Limited, said the company was grateful to God for the privilege of being singled out among all the pharmaceutical companies in Nigeria and given the award.
He added that the company was glad and proud to be recognised for contributing to health care services, not only in Lagos State but in the whole country, stressing that the company, along with its principal partner, Ajanta-India, had been at the forefront of the national malaria control programme of the Federal Government of Nigeria and had also participated actively in the malaria programme of WHO, UNICEF and the Global Fund for more than two years.
The Olpharm boss disclosed further that the company, with its product, Olpharm Baby Zinc, had also been at the forefront of the WHO and UNICEF diarrhoeaprogramme.
He stated further that with the Olpharm Baby Zinc, the only product certified by the United States Pharmacopoeia (USP) for diarrhoea in Nigeria, the company had consistently demonstrated its commitment to WHO and UNICEF programmes of helping to provide quality health care to the under-five. This, Pharm. Olusetire said, would help the government and other partners in meeting the Millennium Development Goal 4.
The Olpharm helmsman also assured that aside consolidating on its programmes and success in helping to achieve the MDG Goal 4 through the provision of quality medicine and care for the under-five, the company would equally focus more on maternal health care in 2014.
He revealed that the company would introduce products for maternal health care in the New Year to help complement efforts of the federal and state governments to reduce maternal mortality in the country.
He also stated that Olpharm, in partnership with Ajanta, would also expand its scope in anticancer products because the incidence of the ailment had been on the increase in the country, adding that the country was already involved in fighting the condition through partnership with teaching hospitals and some private and specialist hospitals.